DOCSLIB.ORG

Acetylcholinesterase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acetylcholinesterase AChE Acetylcholinesterase Acetylcholinesterase (AChE or acetylhydrolase) is a hydrolase that hydrolyzes the neurotransmitter acetylcholine. AChE is found at mainly neuromuscular junctions and cholinergic brain synapses, where its activity serves to terminate synaptic transmission. It belongs tocarboxylesterase family of enzymes. It is the primary target of inhibition by organophosphorus compounds such as nerve agents and pesticides. AChE has a very high catalytic activity - each molecule of AChE degrades about 25000 molecules ofacetylcholine (ACh) per second, approaching the limit allowed by diffusion of the substrate. ACh is released from the nerve into the synaptic cleft and binds to ACh receptors on the post-synaptic membrane, relaying the signal from the nerve. AChE, also located on the post-synaptic membrane, terminates the signal transmission by hydrolyzing ACh. The liberated choline is taken up again by the pre-synaptic nerve and ACh is synthetized by combining with acetyl-CoA through the action of choline acetyltransferase. www.MedChemExpress.com 1 AChE Inhibitors & Activators (+)-Phenserine (-)-Corynoxidine Cat. No.: HY-16009 Cat. No.: HY-N7010 (+)-Phenserine is a novel selective cholinesterase (-)-Corynoxidine is an acetylcholinesterase noncompetitive inhibitor with an IC50 of 45.3 μM. inhibitor with an IC50 value of 89.0 μM, isolated from the aerial parts of Corydalis speciosa. (-)-Corynoxidine exhibits antibacterial activities against Staphylococcus aureus and methicillin-resistant S. Purity: 98.09% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg Size: 1 mg, 5 mg (-)-Huperzine A (R)-Rivastigmine D6 tartrate (Huperzine A) Cat. No.: HY-17387 Cat. No.: HY-11017AS (-)-Huperzine A (Huperzine A) is an alkaloid (R)-Rivastigmine D6 tartrate is the deuterium isolated from a Chinese club moss, with labeled (R)-Rivastigmine, which is an neuroprotective activity. cholinesterase inhibitor. Purity: ≥98.0% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg Size: 1 mg, 5 mg (±)-Huperzine A 1-Naphthyl acetate Cat. No.: HY-17388 Cat. No.: HY-W016188 (±)-Huperzine A, an active Lycopodium alkaloid 1-Naphthyl acetate is an attractive chromogenic extracted from traditional Chinese herb, is a substrate for the detection of erythrocyte potent, selective and reversible acetylcholinesterase (AChE) activity. 1-Naphthyl acetylcholinesterase (AChE) inhibitor and has been acetate has the potential to detect widely used in China for the treatment of organophosphorus pesticide (OP) poisoning. Alzheimer's disease (AD). Purity: ≥98.0% Purity: 99.98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 10 mM × 1 mL, 500 mg 4-Methylbenzylidene camphor Acephate (4-MBC; Enzacamene) Cat. No.: HY-17587 Cat. No.: HY-B0841 4-Methylbenzylidene camphor(4-MBC; Enzacamene)is Acephate is an anticholinesterase insecticide that an organic camphor derivative that is used in the produces cholinotoxicity. Acephate displays weak cosmetic industry for its ability to protect the inhibition of rat AChE but potently inhibits skin against UV, specifically UV B radiation. cockroach AChE. Purity: 99.86% Purity: ≥98.0% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g Size: 50 mg, 100 mg Acetylshikonin AChE/BChE-IN-1 Cat. No.: HY-N2181 Cat. No.: HY-131971 Acetylshikonin, derived from the root of AChE/BChE-IN-1 is a potent and brain-penetrant Lithospermum erythrorhizon, has anti-cancer and dual inhibitor of Acetylcholinesterase and antiinflammation activity. Acetylshikonin is a Butyrylcholinesterase, with IC50s of 1.06 and 7.3 non-selective cytochrome P450 inhibitor nM for hAChE and hBChE, respectively. against all P450s (IC50 values range from 1.4-4.0 AChE/BChE-IN-1 also has antioxidant activity. μM). Purity: 98.06% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg, 10 mg, 20 mg Size: 1 mg, 5 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Acotiamide monohydrochloride trihydrate Ajmalicine Cat. No.: HY-B2155 (Raubasine) Cat. No.: HY-N1919 Acotiamide monohydrochloride trihydrate is an Ajmalicine (Raubasine) is found in herbs of orally active and first-in-class gastroprokinetic Catharanthus roseus, is an antihypertensive drug agent for the treatment of functional dyspepsia. used in the treatment of high blood pressure, decreases peripheral resistance and blood pressure. Purity: 99.28% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 1 mg, 5 mg Aldicarb sulfone Azamethiphos Cat. No.: HY-17530 Cat. No.: HY-114899 Aldicarb sulfone(Temik sulfone) is a carbamate Azamethiphos is an organophosphate insecticide and insecticide; is a cholinesterase inhibitor which a neurotoxic agent, causing acetylcholinesterase prevents the breakdown of acetylcholine in the (AChE) inhibition. synapse. Purity: 99.24% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 1 mg, 5 mg Benactyzine hydrochloride BuChE-IN-TM-10 Cat. No.: HY-B1542A (TM-10) Cat. No.: HY-114320 Benactyzine hydrochloride is a BuChE-IN-TM-10 (TM-10) is a potent butyrylcholinesterase (BChE) inhibitor with a Ki butyrylcholinesterase (BuChE) inhibitor, with an of 0.010 mM. IC50 of 8.9 nM. BuChE inhibitor 1 inhibits and disaggregates self-induced Aβ aggregation, exhibiting potent antioxidant activity and good blood-brain barrier (BBB) penetration. Purity: 99.69% Purity: >98% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 1 mg, 5 mg Chlorpyrifos Chlorpyrifos-oxon Cat. No.: HY-B0815 Cat. No.: HY-136610 Chlorpyrifos is an organophosphate insecticide Chlorpyrifos-oxon, an active metabolite of that is classified as a phosphorothionate. The Chlorpyrifos, is a potent phosphorylating agent oxon metabolite of Chlorpyrifos is an inhibitor of that potently inhibits AChE. Chlorpyrifos-oxon acetylcholinesterase (AChE), affecting can induce cross-linking between subunits of neurological function in insects, humans, and tubulin and disrupt microtubule function. other animals. Purity: ≥98.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 50 mg, 100 mg Size: 1 mg, 5 mg Corydaline Corynoline ((+)-Corydaline; Corydalin) Cat. No.: HY-N0923 Cat. No.: HY-N0826 Corydaline ((+)-Corydaline), an isoquinoline Corynoline, isolated from Corydalis incise alkaloid isolated from Corydalis yanhusuo, is an (Papaveraceae), is a reversible and noncompetitive AChE inhibitor with an IC50 of 226 µM. Corydaline acetylcholinesterase (AChE) inhibitor with an is a μ-opioid receptor (Ki of 1.23 µM) agonist and IC50 of 30.6 μM. Corynoline exhibits inhibits enterovirus 71 (EV71) replication (IC50 anti-inflammatory activity by activating Nrf2. of 25.23 µM). Purity: 96.17% Purity: 98.06% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg www.MedChemExpress.com 3 Coumaran Cyanidin-3-O-galactoside chloride (2,3-Dihydrobenzofuran) Cat. No.: HY-75247 (Ideain chloride) Cat. No.: HY-N4142 Coumaran (2,3-Dihydrobenzofuran) is an Cyanidin-3-O-galactoside chloride (Ideain acetylcholinesterase (AChE) inhibitor isolated chloride) is a component from extract peel of from leaves of L. camara. Coumaran can be used hawthorn fruit (EPHF) with the value of 179.4 as a biopesticide. mg/g. EPHF exhibits strong AChE inhibitory activity. Purity: 99.69% Purity: 99.20% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 500 mg Size: 1 mg, 5 mg Dehydronuciferine Demecarium Bromide Cat. No.: HY-N4261 (BC-48) Cat. No.: HY-B1626A Dehydronuciferine is isolated from the leaves of Demecarium Bromide (BC-48) is a potent Nelumbo nucifera Gaertn, a acetylcholinesterase cholinesterase inhibitor, with an apparent affinity (AChE) inhibitor with an IC50 of 25 μg/mL. (Kiapp) of 0.15 μM. Demecarium Bromide (BC-48) is used as a glaucoma agent. Purity: ≥99.0% Purity: ≥95.0% Clinical Data: No Development Reported Clinical Data: Launched Size: 5 mg, 10 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg Dihydro Donepezil Dihydrowithaferin A (Dihydro E2020) Cat. No.: HY-131252 (2,3-Dihydrowithaferin A) Cat. No.: HY-N5120 Dihydro Donepezil (Dihydro E2020) is a metabolite Dihydrowithaferin A (2, 3-dihydrowithaferin A) is of Donepezil. Donepezil is a specific and potent a withanolide isolated from Withania AChE inhibitor with IC50s of 8.12 nM and 11.6 nM somnifera. Dihydrowithaferin A is active for bAChE and hAChE, respectively. against acetylcholinesterase (AChE). Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 5 mg Size: 1 mg, 5 mg Donepezil Donepezil Hydrochloride (E2020 free base) Cat. No.: HY-14566 (E2020) Cat. No.: HY-B0034 Donepezil (E2020 free base) is a specific and Donepezil (Hydrochloride) (E-2020) is a potent AChE inhibitor with IC50s of 8.12 nM and noncompetitive acetylcholinesterase inhibitor, 11.6 nM for bovine AChE and human AChE, which can readily cross the blood brain barrier respectively. and increases the concentration of cortical acetylcholine. Purity: 99.96% Purity: 99.97% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10
Load more

Recommended publications
  • Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal
    testinal & in D o i tr g s e Journal of Gastrointestinal & a s t G i v f e o Narayanan et al., J Gastrointest Dig Syst 2018, 8:1 S l y a s n r ISSN: 2161-069Xt Digestive System DOI: 10.4172/2161-069X.1000553 e u m o J Research Article Open Access Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal- related Symptoms of Functional Dyspepsia Varsha Narayanan*, Amit Bhargava and Shailesh Pallewar 1Department of Medical Services and Research, Lupin Ltd., India *Corresponding author: Narayanan V, Department of Medical Services and Research, Lupin Ltd., Mumbai, India, Tel: +912266402222; E-mail: [email protected] Received date: February 09, 2018; Accepted date: February 21, 2018; Published date: February 27, 2018 Copyright: © 2018 Narayanan V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Functional Dyspepsia (FD) is a highly prevalent clinical condition that imposes negative economic burden on health-care system as well as greatly impairs quality of life. Treatment of non-specific and bothersome meal-related FD symptoms like post-prandial fullness, upper abdominal bloating and early satiety, is a therapeutic challenge for the clinicians as poorly-defined and ill-understood pathogenesis has hampered efforts to develop effective treatments. Acotiamide is first-in-class drug that exerts its gastro-kinetic effect by enhancing acetylcholine release. Though evidence of its efficacy and tolerance are available through randomized clinical trials, real world data from its regular in-clinic use is lacking.
    [Show full text]
  • PN0496-Acotiamide.Pdf
    Acotiamide hydrochloride hydrate (Acofide®) 盐酸阿考替胺 Z-338 in Zeria; YM-443 in Astellas Tablet, oral, EQ 100 mg acotiamide Acotiamide is a peripheral acetylcholinesterase inhibitor, indicated for the treatment of functional dyspepsia (FD), which was first-in-class drug to treat FD in the world and approved in 2013 by Japan PMDA. It was originally discovered by Zeria, and co-developed with Astellas. The drug is co-marketing in Japan with a single brand name. The human recommended starting dose is 100 mg at a time, and 3 times a day before meals. Worldwide Key Approvals Global Sales ($Million) Key Substance Patent Expiration 2016-May (US5981557A) 2016-May (EP0870765B1) 2013-Mar (JP) Not available 2021-May (JP3181919B2) 2016-May (CN1063442C) Mechanism of Action Acotiamide hydrochloride hydrate is an acetylcholinesterase (AChE) inhibitor and enhanced the acetylcholine (ACh)-induced contraction and motility of the gastric antrum and the gastric body. Target Binding Selectivity In vitro Efficacy In vivo Efficacy Mixed pattern: Ki1= 0.61 µM Effect dose of contraction in gastric sample: Significantly improved the gastrointestinal motility: Ki2= 2.7 µM ACh-induced: at 1 µM In normal and gastric hypomotility dogs: at 10 mg/kg. Inhibition: IC50= 3 µM Electrical-induced: at 0.3 µM In gastric hypomotility rats: at 100 mg/kg. Pharmacokinetics Parameters Rats Dogs Healthy Humans 3 10 3 10 50 mg 100 mg 200 mg 400 mg 800 mg Dose (mg/kg) (i.v.) (p.o.) (i.v.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) Tmax (hr) - 0.08 - 0.5 2.75 2.42 2.08 2.25 2.13 Cmax
    [Show full text]
  • Β-Phenylethylamines and the Isoquinoline Alkaloids
    -Phenylethylamines and the isoquinoline alkaloids Kenneth W. Bentley Marrview, Tillybirloch, Midmar, Aberdeenshire, UK AB51 7PS Received (in Cambridge, UK) 28th November 2000 First published as an Advance Article on the web 7th February 2001 Covering: July 1999 to June 2000. Previous review: Nat. Prod. Rep., 2000, 17, 247. 1 Introduction 2 -Phenylethylamines 3 Isoquinolines 4 Naphthylisoquinolines 5 Benzylisoquinolines 6 Bisbenzylisoquinolines 7 Pavines and isopavines 8 Berberines and tetrahydoberberines 9 Protopines 10 Phthalide-isoquinolines 11 Other modified berberines 12 Emetine and related alkaloids 13 Benzophenanthridines 14 Aporphinoid alkaloids 14.1 Proaporphines 14.2 Aporphines 14.3 Aporphine–benzylisoquinoline dimers 14.4 Phenanthrenes 14.5 Oxoaporphines 14.6 Dioxoaporphines 14.7 Aristolochic acids and aristolactams 14.8 Oxoisoaporphines 15 Alkaloids of the morphine group 16 Colchicine and related alkaloids 17 Erythrina alkaloids 17.1 Erythrinanes 17.2 Cephalotaxine and related alkaloids 18 Other isoquinolines 19 References 1 Introduction Reviews of the occurrence of isoquinoline alkaloids in some plant species 1,2 and of recent developments in the chemistry and synthesis of alkaloids of these groups 3–6 have been published. 2 -Phenylethylamines β-Phenylethylamine, tyramine, N-methyltyramine, hordenine, mescaline, N-methylmescaline and N,N-dimethylmescaline 1, which is reported as an alkaloid for the first time, have been isolated from an unspecified species of Turbinocarpus 7 and N-trans-feruloyltyramine has been isolated from Cananga odorata.8 The N-oxides of the known alkaloid culantraramine 2 and the unknown culantraraminol 3, together with the related avicennamine 4 have been isolated as new alkaloids from Zanthoxylum avicennae.9 Three novel amides of dehydrotyr- leucine and proline respectively.
    [Show full text]
  • Development of Microplate Screening System
    DEVELOPMENT OF MICROPLATE SCREENING SYSTEM AND CONSTRUCTION OF FLUORESCEIN-BASED LIBRARY FENG SUIHAN A THESIS SUMBITTED FOR THE DEGREE OF MASTER OF SCIENCE DEPARTMENT OF CHEMISTRY NATIONAL UNIVERSITY OF SINGAPORE 2010 Acknowledgements First of all, I would like to express my deep gratitude to my supervisor, Associate Professor Young-Tae Chang for his profound knowledge, invaluable guidance, constant support and inspiration throughout my graduate studies. The knowledge, both scientific and otherwise, that I accumulated under his supervision, will aid me greatly throughout my life. Next, I would like to give my sincere thanks to Dr. Marc Vendrell and Dr. Hyung-Ho Ha, for their warm support during my entire graduate studies. Besides, my sincere thinks goes to Miss Siqiang Yang, who helped me to set up the microplate screening platform. Also, I would like to thank all the graduate students of Chang lab, Animesh, Duanting, Ghosh, Jun-Seok, Yun-Kyung, Raj, for their cordiality and friendship. We had a great time together. I also benefited from all other lab members, particularly but not limited to, Siti, Yee Ling, Chew Yan, Xubin, Jeffrey, Shin Hui, Dr. Bi, Dr. Cho, Dr. Jun Li, Dr. Lees, Dr. Kang, Dr. Kim, Dr. Park, and etc. Thanks for making the working place an enjoyable one. I am grateful to Dr. Tan for recruiting me into NUS Medicinal Chemistry graduate program and I am also thankful to NUS for awarding me the research scholarship. At last, I would like to express greatest thanks to my family, particularly my wife, Bai Yang, whose encourage and understanding help me to finish my graduate study in NUS.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • 2020 Welldyne Formulary.Pdf
    LEGEND TIER DESCRIPTION 1 Preferred Generics 2 Non-Preferred Generics 3 Preferred Brands 4 Non-Preferred Brands 5 Preferred Specialty 6 Non-Preferred Specialty TYPE DESCRIPTION There is a limit on the amount of this drug that is covered per QL Quantity Limit prescription, or within a specific time frame. You (or your physician) are required to get prior authorization before PA Prior Authorization you fill your prescription for this drug. Without prior approval, we may not cover this drug. In some cases, you may be required to first try certain drugs to treat ST Step Therapy your medical condition before we will cover another drug for that condition. This prescription drug may only be covered if you meet the minimum AL1 Age Limit or maximum age limit. LA Limited Access This prescription drug is limited to certain pharmacies. Specialty drugs are high-cost drugs used to treat complex or rare S Specialty Drug conditions, such as multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. PAGE 1 LAST UPDATED 01/2020 LIST OF COVERED PRESCRIPTION MEDICATIONS PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ADHD/ANTI-NARCOLEPSY /ANTI-OBESITY/ANOREXIANT AGENTS ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS ADDERALL 4 AL1 Up to 25 yrs old ADDERALL XR 4 AL1 Up to 25 yrs old QL 30 / 30 day(s) ADHANSIA XR 4 AL1 Up to 25 yrs old QL 30 / 30 Days ADIPEX-P 4 PA QL 300 / 30 day(s) ADZENYS ER 4 AL1 Up to 25 yrs old QL 30 / 30 Days ADZENYS XR-ODT 4 AL1 Up to 25 yrs old QL 300 / 30 day(s) AMPHETAMINE ER 4 AL1 Up to 25 yrs old QL 180 / 30 day(s) amphetamine
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Modulation of Ion Channels by Natural Products ‒ Identification of Herg Channel Inhibitors and GABAA Receptor Ligands from Plant Extracts
    Modulation of ion channels by natural products ‒ Identification of hERG channel inhibitors and GABAA receptor ligands from plant extracts Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Anja Schramm aus Wiedersbach (Thüringen), Deutschland Basel, 2014 Original document stored on the publication server of the University of Basel edoc.unibas.ch This work is licenced under the agreement „Attribution Non-Commercial No Derivatives – 3.0 Switzerland“ (CC BY-NC-ND 3.0 CH). The complete text may be reviewed here: creativecommons.org/licenses/by-nc-nd/3.0/ch/deed.en Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von Prof. Dr. Matthias Hamburger Prof. Dr. Judith Maria Rollinger Basel, den 18.02.2014 Prof. Dr. Jörg Schibler Dekan Attribution-NonCommercial-NoDerivatives 3.0 Switzerland (CC BY-NC-ND 3.0 CH) You are free: to Share — to copy, distribute and transmit the work Under the following conditions: Attribution — You must attribute the work in the manner specified by the author or licensor (but not in any way that suggests that they endorse you or your use of the work). Noncommercial — You may not use this work for commercial purposes. No Derivative Works — You may not alter, transform, or build upon this work. With the understanding that: Waiver — Any of the above conditions can be waived if you get permission from the copyright holder. Public Domain — Where the work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    [Show full text]
  • Drug-Like Properties and ADME of Xanthone Derivatives: the Antechamber of Clinical Trials Ana Sara Gomes, Pedro Brandão, Carla
    Drug-like properties and ADME of xanthone derivatives: the antechamber of clinical trials Ana Sara Gomes, Pedro Brandão, Carla Fernandes, Marta Correia-da-Silva, Emília Sousa*, Madalena Pinto# # all authors contributed equally to this work *corresponding author Abstract Xanthone derivatives have been described as compounds with privileged scaffolds that exhibited diverse interesting biological activities, such as antitumor activity, directing the interest to pursue the development of these derivatives into drug candidates. Nevertheless, to achieve this purpose it is crucial to study their pharmacokinetics and toxicity (PK/tox) as decision endpoints to continue or interrupt the development investment. This review aims to expose the most relevant analytical methods used in physicochemical and PK/tox studies in order to detect, quantify and identify different bioactive xanthones. Also the methodologies used in the mentioned studies, and the main obtained results, are referred to understand the drugability of xanthones derivatives through in vitro and in vivo systems towards ADME/tox properties, such as physicochemical and metabolic stability and biovailability. The last section of this review focus on a case-study of the development of the drug candidate DMXAA, which has reached clinical trials, to understand the paths and the importance of PK/tox studies. In the end, the data assembled in this review intends to facilitate the design of potential drug candidates with a xanthonic scaffold. Xanthone; analytical method; drug-like; pharmacokinetics; toxicity; drug development; preclinical; metabolism; chromatography. 1. Introduction The xanthone nucleus or 9H-xanthen-9-one (dibenzo-γ-pirone 1, Fig. 1) comprises an important class of oxygenated heterocycles and is considered a privileged structure 1.
    [Show full text]